0000899243-23-002674.txt : 20230125
0000899243-23-002674.hdr.sgml : 20230125
20230125180431
ACCESSION NUMBER: 0000899243-23-002674
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230123
FILED AS OF DATE: 20230125
DATE AS OF CHANGE: 20230125
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Meisner Lara
CENTRAL INDEX KEY: 0001883986
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36483
FILM NUMBER: 23553417
MAIL ADDRESS:
STREET 1: C/O VIRIDIAN THERAPEUTICS, INC.
STREET 2: 203 CRESCENT STREET, BLDG. 17, SUITE 102
CITY: WALTHAM
STATE: MA
ZIP: 02453
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Viridian Therapeutics, Inc.\DE
CENTRAL INDEX KEY: 0001590750
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071]
IRS NUMBER: 471187261
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 203 CRESCENT STREET
STREET 2: BLDG. 17, SUITE 102B
CITY: WALTHAM
STATE: MA
ZIP: 02453
BUSINESS PHONE: 617.272.4600
MAIL ADDRESS:
STREET 1: 203 CRESCENT STREET
STREET 2: BLDG. 17, SUITE 102B
CITY: WALTHAM
STATE: MA
ZIP: 02453
FORMER COMPANY:
FORMER CONFORMED NAME: MIRAGEN THERAPEUTICS, INC.
DATE OF NAME CHANGE: 20170213
FORMER COMPANY:
FORMER CONFORMED NAME: MIRAGEN THERAPEUTICS, INC.
DATE OF NAME CHANGE: 20170213
FORMER COMPANY:
FORMER CONFORMED NAME: SIGNAL GENETICS, INC.
DATE OF NAME CHANGE: 20140710
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2023-01-23
0
0001590750
Viridian Therapeutics, Inc.\DE
VRDN
0001883986
Meisner Lara
C/O VIRIDIAN THERAPEUTICS, INC.
221 CRESCENT STREET, SUITE 401
WALTHAM
MA
02453
0
1
0
0
General Counsel and Secretary
Common Stock
2023-01-23
4
M
0
4971
23.03
A
4971
D
Common Stock
2023-01-23
4
M
0
1872
14.00
A
6843
D
Common Stock
2023-01-23
4
S
0
6843
35.66
D
0
D
Stock Option (Right to Buy)
23.03
2023-01-23
4
M
0
4971
0.00
D
2031-01-18
Common Stock
4971
39750
D
Stock Option (Right to Buy)
14.00
2023-01-23
4
M
0
1872
0.00
D
2031-09-22
Common Stock
1872
20003
D
This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $35.22 to $36.06. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
The option vested 25% on December 2, 2021 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date.
The option vested 25% on September 22, 2022 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date.
/s/ Kristian Humer, Attorney-in-Fact for Lara Meisner
2023-01-25